Provista Diagnostics, Inc., a Delaware company, is a privately held molecular diagnostics company offering diagnostic testing and reference clinical laboratory services tot he pharmaceutical and biotechnology industries. Additionally, the company is focused on developing and commercializing its own proprietary diagnostic, prognostic and predictive tests for cancers affecting women through its dtectDx platform. Provista develops and commercializes breakthrough, easy to administer blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes. The Company’s focus is on oncology-related diagnostics where a significantly high, unmet clinical need for such testing products exist.
The laboratory services, such as biomarker research and evaluation, product commercialization evaluation, grant support, and laboratory support services. It also provides contract research services and technologies, including consultation, assay evaluation and development, method development, clinical laboratory services, analytical regulatory guidance, companion diagnostics development, qualittative and quantitative immunochemistry, advanced protein analysis, and sequencing services to the pharmaceutical and biotechnology industries.
Provista Diagnostic’s technologies are developed at our CLIA accredited, GLP capable, 13,610 sq/ft laboratory facility based in Scottsdale, Arizona. Recently, Provista has opened an office in New York to take advantage of the sales, marketing, regulatory and financial expertise in the region.
Categories: cancer, COMPANIES, Diagnostics, Technology Report
